Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-10T11:45:15.319Z Has data issue: false hasContentIssue false
  • English
  • Français

Calidad de vida y costes de tratamiento en pacientes ambulatorios esquizofrénicos tratados con neurolépticos depot

Published online by Cambridge University Press:  12 May 2020

M.Z. Dernovsek ,
V. Prevolnik Rupel ,
M. Rebolj  and
R. Tavcar
M.Z. Dernovsek
Affiliation:
Hospital Psiquiátrico Universitario, Studenec 48, SI-1260Ljubljana-Polje, Eslovenia;
V. Prevolnik Rupel
Affiliation:
Ministerio de Salud, Stefanova 5, SI-1000Ljubjana, Eslovenia;
M. Rebolj
Affiliation:
Escuela de Economía, Kardaljeva ploscad 17, SI-1000Ljubljana, Eslovenia
R. Tavcar
Affiliation:
Hospital Psiquiátrico Universitario, Studenec 48, SI-1260Ljubljana-Polje, Eslovenia;
Get access

Resumen

El propósito del estudio era 1) descubrir las influencias en la calidad de vida (CDV) de los pacientes ambulatorios crónicos con esquizofrenia, 2) calcular los años de vida ajustados según la calidad (AVAC), y 3) estimar los costes directos de un año de tratamiento. En una muestra del 20% (100 varones, 100 mujeres) de los pacientes ambulatorios esquizofrénicos de la Clínica Ambulatoria en Ljubljana, Eslovenia, que recibían neurolépticos depot, se recogieron los datos demográficos, clínicos y de tratamiento para el año 1996. Se utilizó la Escala de Krawiecka, la Escala de Evaluación Global (GAS), la Escala de Movimientos Involuntarios Anormales, la Escala de Evaluación para la Acatisia Inducida por los Medicamentos, la Escala de Evaluación para los Efectos Secundarios Extrapiramidales, la Escala de Calidad de Vida (QLS), la EQ-5D y los AVAC. Se utilizó regresión lineal multivariable con la puntuación de la QLS como variable dependiente. Los pacientes tenían 44 años de media y habían recibido tratamiento durante 14 años. La puntuación media de la GAS era 70. La GAS se relacionaba positivamente con la puntuación de la QLS, mientras que la puntuación de parkinsonismo estaba correlacionada inversamente con la QLS. Los pacientes pueden esperar vivir 10,20 más AVAC como media. La CDV en la escala EQ-5D era 0,73. Los costes directos del tratamiento anual ascendían a 216,216$ en precios de 1996. En pacientes crónicos bien ajustados con esquizofrenia, la CDV parece depender sobre todo de su rendimiento psicosocial y los efectos secundarios. Aunque infrecuentes, las nuevas hospitalizaciones explicaban la mitad de todos los gastos de tratamiento.

Keywords

pacientes ambulatorioscalidad de vidanuevas hospitalizacionesesquizofrenia
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 9 , Issue 4 , May 2002 , pp. 226 - 235

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl):1-63.CrossRefGoogle Scholar
Attikisson, CCook, JKarno, MLehman, AMcGlashan, THMeltzer, HY.Caring for people with severa mental disorders: clinical services research. Schizophr Bull 1992;18:561-626.CrossRefGoogle Scholar
Awad, AG.Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992;43:262-5.Google ScholarPubMed
Awad, AGHogan, TP.Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994;89(Suppl 380):27-31.CrossRefGoogle Scholar
Bank of Slovenia. Bilten Banke Slovenije 1997;6:10.Google Scholar
Barnes, TRE.A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672-6.CrossRefGoogle ScholarPubMed
Bellack, ASMorrison, RLWixted, JTMueser, KT.An analysis of social competence in schizophrenia. Br J Psychiatry 1990;156:809-18.CrossRefGoogle Scholar
Bobes, JGutierrez, MGibert, JGonzalez, MPHerraiz, LFernandez, A.Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatry 1998;13:158-63.CrossRefGoogle ScholarPubMed
Browne, SClarke, MGervin, MWaddington, JLLarkin, CO’Callaghan, E.Quality of life after treatment for a first presentation of schizophrenia. Schizophr Res 2000;41(Suppl):301.CrossRefGoogle Scholar
Casey, DE.Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand 1994;89(Suppl 380):14-20.CrossRefGoogle Scholar
Doyle, MFlanagan, SBrowne, SClarke, MLydon, DLarkin, C, et al.Subjective and external assessments of qualiy of life in schizophrenia: relationship to insight. Acta Psychiatr Scand 1999;99:466-72.CrossRefGoogle Scholar
Endicott, JSpitzer, RLFleiss, JLCohen, JC.The global assessment scale-a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-71.CrossRefGoogle ScholarPubMed
EuroQol EQ-5D. User guide: version B. Rotterdam: EuroQol Office; 1998.Google Scholar
Evans, RW.Quality of life. Lancet 1991;338:636.CrossRefGoogle Scholar
Foster, RHGoa, KL.Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999;15:611-40.CrossRefGoogle Scholar
Gudox, CKind, Pvan Dalen, HDurand, MAMorris, JWilliams, A.Comparing scaling methods for health State valuations-Rosser revisited. Discussion paper 107: Centre for Health Economics York; 1993.Google Scholar
Halford, WKHayes, RL.Social skills in schizophrenia: assessing the relationship between social skills, psychopathology and community functioning. Soc Psychiatry Psychiatr Epidemiol 1995;30:14-9.CrossRefGoogle ScholarPubMed
Hargreaves, WAShumway, MHu, TCuffel, B.Cost-outcome methods for mental health. San Diego: Academic Press; 1998. p. 160-2.Google Scholar
Harwood, REbrahim, S.Quality of life. Lancet 1991;338:637.Google Scholar
Heinrichs, DWHanlon, TECarpenter, WT.The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.CrossRefGoogle ScholarPubMed
Heslegrave, RJVoruganti, LNPAwad, AG.Neuropsychiatric correlates of quality of life in psychiatry in schizophrenia. Schizophr Res 1995;12:216-7.CrossRefGoogle Scholar
Johnson, DAWWright, NF.Drug prescribing for schizophrenic out-patients on depot injections. Br J Psychiatry 1990;156:827-34.CrossRefGoogle ScholarPubMed
Kissling, W.Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1994;89(Suppl 382):16-24.CrossRefGoogle Scholar
Knapp, M.Costs of schizophrenia. BrJ Psychiatry 1997;171:509-18.CrossRefGoogle ScholarPubMed
Koopmanschap, MARutten, FFHvan Ineveld, BMvan Roijen, L.The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.CrossRefGoogle ScholarPubMed
Krawiecka, MGoldberg, DVaughan, M.A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Stand 1977;55:299-308.CrossRefGoogle ScholarPubMed
Larsen, EBGerlach, J.Subjective experience of treatment, side effects, mental State and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Stand 1996;93:381-8.CrossRefGoogle ScholarPubMed
Meltzer, HYBurnett, SBastani, BRamirez, LF.Effects of six months of dozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7.Google Scholar
Meltzer, HY.Dimensions of outcome with clozapine. Br J Psychiatry 1992;160(Suppl 17):46-53.CrossRefGoogle Scholar
Munetz, MRBenjamin, S.How to examine patient using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39:1172-7.Google ScholarPubMed
National Health Insurance Institute of Slovenia. Poslovno porocilo Zavoda za zdravstveno zavarovanje Slovenije za leto 1996. Ljubljana: National Health Insurance Institute of Slovenia; 1997.Google Scholar
O’Boyle, CMcGee, HHickey, AO’Malley, KJoyce, C.Individual quality of life in patients undergoing hip replacement. Lancet 1992;339:1088-91.CrossRefGoogle ScholarPubMed
O’Boyle, C.The schedule for the evaluation of individual quality of life. Int J Ment Health 1994;23:3-23.CrossRefGoogle Scholar
Pinkney, AAGerber, GJLafave, HG.Quality of life after psychiatric rehabilitation: the clients' perspective. Acta Psychiatr Stand 1991;83:86-91.CrossRefGoogle ScholarPubMed
Public Health Institute of Slovenia. Zdravstveni statisticni letopis 1996. Zdrav Var 1997;36(Suppl 4):312.Google Scholar
Read, JLQuinn, RJHoefer, JVLA.Measuring overall health: an evaluation of three important approaches. J Chron Dis 1987;40:7-21.CrossRefGoogle ScholarPubMed
Schooler, NRKane, JM.Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7.Google ScholarPubMed
Shtasel, PLGur, REGallacher, FHeimberg, CGur, R.Gender differences in the clinical expression of schizophrenia. Schizophr Res 1992;7:225-31.CrossRefGoogle ScholarPubMed
Simpson, GMAngus, JWS.A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;12(Suppl 44):11-9.CrossRefGoogle Scholar
Skantze, KMalm, UDencker, SMay, PCorrigan, P.Comparison of quality of life with standard of living in schizophrenic outpatients. Br J Psychiatry 1992;161:797-801.CrossRefGoogle Scholar
Statistical Office of the Republic of Slovenia. Statisticni letopis 1997, Volume XXXVI. Ljubljana: Statistical Office of the Republic of Slovenia; 1997.Google Scholar
Tavcar, RDernovsek, MZ.Recidivism in Slovenia. Psychiatr Serv 1997;48:955-6.Google ScholarPubMed
Tavcar, RDernovsek, MZZvan, V.Choosing antipsychotic maintenance therapy. A naturalistic study. Pharmacopsychiatry 2000;33:66-71.CrossRefGoogle ScholarPubMed
Weiden, PAquila, RStandard, J.Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl. 11):53-60.Google Scholar
Zvan, V.Nacela vzdrzevalne nevrolepticne terapije psihoz. Zdrav Var 1989;28:335-41.Google Scholar